SLNO Soleno Therapeutics tops Q4 2025 EPS estimates by 103 percent shares edge 021 percent lower today Federal Reserve Headquarters Renovation Dispute and Governance Analysis Is Forte Biosciences FBRX stock respecting technical levels Q4 2025 Earnings Fall Short